A new specialised team dedicated to QIAGEN brings Quilaban’s support even closer to its customers.
In 2025, Quilaban and QIAGEN will reinforce their strategic partnership in Portugal, consolidating a relationship of over 20 years in the service of healthcare innovation. Their shared goal remains unchanged: to promote access to high-quality, innovative laboratory solutions with a direct impact on diagnostics.
At present, more than 50 laboratories and institutions within Portugal’s National Health Service use QIAGEN technologies, supported by Quilaban’s technical, scientific, and commercial expertise. This collaboration has made it possible to respond efficiently and in a tailored way to the growing challenges of public health.
We are the exclusive representatives of the latent tuberculosis screening test – QuantiFERON-Plus – as well as syndromic panels (respiratory, meningitis/encephalitis, and gastrointestinal) with the QIAstat-Dx system and the QiAcuityDx Digital PCR platform, the only one adapted for clinical diagnostics.
This year, the partnership is taking a further step forward with the creation of a specialised team fully dedicated to QIAGEN. This new structure guarantees close and highly qualified support, strengthening the capacity to respond to healthcare professionals and institutions.
Quilaban thus reaffirms its mission to promote access to healthcare and its vision of being the reference partner in the implementation of innovative, efficient, and integrated solutions.